Shop Cilostazol Online in the USA

Cilostazol is a phosphodiesterase III inhibitor with antiplatelet and vasodilatory activity. By elevating intracellular cAMP in platelets and vascular smooth muscle, it reduces platelet aggregation and improves limb perfusion, making it mainly indicated for intermittent claudication in peripheral arterial disease.

Overview of Cilostazol and its drug class

Cilostazol is a selective phosphodiesterase type III inhibitor. Its pharmacologic effects include inhibition of platelet activation and vasodilation, mediated by increased cyclic AMP within platelets and vascular smooth muscle cells.

As a member of the vasodilating antiplatelet class, cilostazol is used to improve walking distance in patients with peripheral arterial disease. It is administered orally and may require careful consideration of hepatic function and potential drug interactions due to metabolism by hepatic cytochrome P450 enzymes (CYP3A4 and CYP2C19).

How it compares to related substances in the same class

Within the spectrum of intermittent claudication therapies, cilostazol provides a dual action of antiplatelet effect and vasodilation via PDE3 inhibition. In contrast, pentoxifylline produces rheologic improvements by reducing blood viscosity and enhancing erythrocyte deformability through nonspecific phosphodiesterase inhibition. Naftidrofuryl acts primarily as a peripheral vasodilator with additional receptor-mediated effects.

Clinical experience suggests cilostazol offers more consistent improvement in claudication distance for many patients compared with pentoxifylline, while tolerability differs by individual. Common adverse effects with cilostazol include headache, palpitations, diarrhea, and edema; pentoxifylline often produces GI upset and dizziness; naftidrofuryl can cause headache and flushing. Choice depends on patient comorbidity, drug interactions, and prior response to therapy.

Therapeutic uses

The approved indication is relief of symptoms of intermittent claudication in peripheral arterial disease when exercise alone is insufficient. Cilostazol may be particularly considered for patients who require improvement in walking distance and functional capacity.

Administration is oral, with usual dosing in adults specified by the prescribing information. Treatment duration is guided by clinical response, with reassessment over several weeks to months. It should be integrated with supervised exercise therapy and risk-factor modification; use is contraindicated in congestive heart failure and requires caution in hepatic impairment and with concomitant strong CYP inhibitors or inducers.

Key differences from similar medications

Two to three major alternatives are sometimes used for intermittent claudication. The following table summarizes core distinctions in mechanism, indication, and safety.

Safety profile summary

Adverse effects commonly associated with cilostazol include headaches, diarrhea, palpitations, and edema. Less frequent events may include dizziness or syncope, with greater risk in older patients or those with cardiovascular disease.

Important safety considerations include avoidance in congestive heart failure and careful assessment of drug interactions. Cilostazol is metabolized by CYP3A4 and CYP2C19; coadministration with strong inhibitors or inducers of these enzymes can markedly alter exposure. Monitoring should address blood pressure, heart rate, and hepatic function as indicated by comorbidity and concomitant therapies.